GH Research (NASDAQ:GHRS) Announces Quarterly Earnings Results

GH Research (NASDAQ:GHRS) announced its quarterly earnings data on Thursday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.06, FiscalAI reports.

GH Research Price Performance

Shares of GHRS opened at $15.17 on Friday. The company has a market capitalization of $789.26 million, a P/E ratio of -20.50 and a beta of 1.00. GH Research has a one year low of $7.98 and a one year high of $19.51. The business’s 50 day simple moving average is $15.38 and its 200-day simple moving average is $14.21.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on GHRS. Royal Bank Of Canada upped their target price on shares of GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. HC Wainwright upped their price objective on GH Research from $35.00 to $70.00 and gave the company a “buy” rating in a research note on Monday. TD Cowen reissued a “buy” rating on shares of GH Research in a report on Monday, January 5th. Canaccord Genuity Group raised their target price on GH Research from $35.00 to $39.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of GH Research in a research note on Tuesday, January 6th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.75.

GH Research News Roundup

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: Company beat quarterly estimates and reported solid year‑end cash: GH Research reported $0.23 loss per share vs. a consensus -$0.29 (better-than-expected), completed and presented Phase 2b GH001 data, obtained FDA clearance to begin U.S. clinical investigation, and ended 2025 with $280.7M in cash and marketable securities. GH Research Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Broker support and price‑target action: HC Wainwright reaffirmed a Buy and market commentary published this week included a $70 price target, which is a materially higher target than the current share price and provides bullish analyst support. GH Research (NASDAQ:GHRS) Price Target Raised to $70.00
• Positive Sentiment: Longer‑term estimate improvement: HC Wainwright nudged its FY2029 EPS estimate slightly better (from -$1.12 to -$1.02), signalling some incremental optimism on longer‑horizon economics. (Source: HC Wainwright research notes)
• Neutral Sentiment: Short interest data is effectively meaningless/noisy right now — reported short interest showed 0 shares (with NaN change), implying no actionable short‑interest signal given the data anomalies and very low days‑to‑cover figure.
• Negative Sentiment: Analyst cuts to near‑ and medium‑term EPS: HC Wainwright lowered several forecasts (Q4 2025, FY2025, FY2026, FY2027 and FY2028 EPS were revised lower), which weakens near‑term profitability expectations and helps explain downward pressure despite balanced positives above. HC Wainwright Comments on GH Research FY2030 Earnings

Hedge Funds Weigh In On GH Research

A number of institutional investors and hedge funds have recently bought and sold shares of GHRS. Barclays PLC grew its holdings in shares of GH Research by 63.4% during the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after purchasing an additional 822 shares during the last quarter. Osaic Holdings Inc. lifted its position in GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after buying an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in GH Research during the 2nd quarter worth about $79,000. HRT Financial LP bought a new stake in GH Research during the 4th quarter worth about $202,000. Finally, BNP Paribas Financial Markets increased its position in GH Research by 165.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after acquiring an additional 10,600 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.